research report · SPRO

Spero Therapeutics, Inc.

Johannes Vermeer, Woman Holding a Balance, c. 1664, detail · National Gallery of Art

Viridis’s deep research report, written Nov 12, 2026 from its quarterly report (10-Q for the quarter ended Sep 30, 2026, filed Nov 12, 2026). Written and checked with Anthropic’s Claude models.

your email, no card; what you get

business trajectory

Stable

little material change

financial resilience

Strong

can meet its obligations and fund its plan for two years with money it can count on, with room

Judgments of the business from its filings, not of its shares: no valuation, no advice.

bottom line

Spero is a one-drug immunology developer with no revenue. It is funded by its own cash, not by its approved antibiotic. At September 30, 2026 it held $107.9M of cash after paying $35.0M to license SP001. Excluding that payment, the quarter used about $7.6M of operating cash (my calculation). That is consistent with the company's statement that its cash lasts into the second half of 2029.

Utebzi's payments now go first to noteholders. They hold a $103.0M liability that costs an estimated 15% a year. The quarter tested neither of the two things that decide the case: FDA clearance of SP001's U.S. trial application, and the pace of Utebzi's launch.

what changed this quarter

  • Q3 revenue was $0, against $5.4M a year earlier. The net loss was $44.3M, against $7.4M, and includes $35.0M of acquired in-process research and development.
  • Cash rose from $50.8M at June 30. Inflows were $103.2M of note proceeds; outflows were $3.4M of transaction costs and the $35.0M upfront payment made in August.
  • Stockholders' equity fell to $0.8M from $44.2M at June 30.
  • Runway guidance is now "into the second half of 2029", against "into 2028" in the annual report.
  • BARDA's contract ended July 6 and Everest's license ended August 10. A $100M Jefferies ATM, a program for selling new shares directly into the market, replaced Cantor's under a $300M shelf registration that became effective September 10.

in the full report

Its findings, each with the evidence, the strongest counterpoint and what would prove it wrong:

  • Utebzi pays the noteholders first, and its royalties may net to little
  • The company rests on one antibody whose U.S. path is not cleared
  • The quarter's loss is mostly a one-time payment; cash covers the plan

Then its finances, the quality of its earnings, its management, the case for and against, and what to watch, its claims cited to the filings and checked against them.

read it whole

Your email and the code we send it, no card. The report then opens: a free account has 2 free reports a month from the library, the reports already written. Already have a Viridis account? Use its email, and the report goes on it. You also see what SPRO files, free: its deadlines and its red flags.

Subscribe: your plan’s reports work on any company that files with the SEC, written for you if nobody has asked yet, and each new one on the companies you choose comes as they file.

In Claude or ChatGPT, ask: “What does Viridis's report on SPRO say?” Add Viridis to Claude, or to ChatGPT.